Scarica l'app Stockscreener
40.47
19.66%
6.65
Dopo l'orario di chiusura:
40.65
0.18
+0.44%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CORT Giù?
Forum
Previsione
Corcept Therapeutics Inc Borsa (CORT) Ultime notizie
Corcept Therapeutics Shareholder Alert: ClaimsFiler Reminds - GlobeNewswire
Corcept Therapeutics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Corcept Therapeutics Incorporated - GlobeNewswire Inc.
Corcept Therapeutics (CORT) Climbs 19.7% as Lifyorli Gets FDA OK - Insider Monkey
'Moments like this don't happen every day': Ovarian cancer drug from Peninsula company wins FDA approval - The Business Journals
Why Investors Strapped a Rocket to Corcept Therapeutics Stock on Wednesday - The Globe and Mail
Corcept Therapeutics Receives FDA Approval for Lifyorli - Intellectia AI
Early FDA wins: Corcept’s Lifyorli, Denali’s Avlayah - BioWorld MedTech
CORT ALERT: Hagens Berman Alerts Corcept Therapeutics (CORT) Investors to Securities Class Action Following FDA Rejection and Federal Court Patent Loss - GlobeNewswire Inc.
H.C. Wainwright Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Maintains Target Price $60 - Moomoo
[144] CORCEPT THERAPEUTICS INC SE... | CORT SEC FilingForm 144 - Stock Titan
CORCEPT THERAPEUTICS INCORPORATED (CORT) - MSN
CORT: HC Wainwright Lowers Price Target to $60, Maintains Buy Ra - GuruFocus
HC Wainwright Has Lowered Expectations for Corcept Therapeutics (NASDAQ:CORT) Stock Price - MarketBeat
Corcept Therapeutics (NASDAQ:CORT) Shares Up 10.3%What's Next? - MarketBeat
Corcept Therapeutics (CORT) Gains FDA Nod for Lifyorli in Cancer Treatment - GuruFocus
Corcept Therapeutics Sees Activity Surge as Insider Buys Boost Investor Confidence - StocksToTrade
FDA clears Corcept (CORT) Lifyorli combo for platinum-resistant ovarian cancer - Stock Titan
Corcept Therapeutics shares surge as lead drug gets FDA nod for ovarian cancer - Reuters
FDA Approves Corcept’s Selective Glucocorticoid Receptor Antagonist Lifyorli™ (relacorilant) Plus Nab-Paclitaxel for Treatment of Patients with Platinum-Resistant Ovarian Cancer - Hastings Tribune
US Stocks: Corcept Therapeutics shares surge 32% as lead drug gets FDA nod for ovarian cancer - The Economic Times
Corcept Therapeutics (CORT) Sees Significant Surge Amid Market G - GuruFocus
Corcept Therapeutics Stock Soars as Insider Buys Spur Market Interest - timothysykes.com
Corcept Therapeutics (CORT) Gains as FDA Approves Cancer Drug - GuruFocus
What's Behind The Jump In Corcept Therapeutics Stock? - Benzinga
Corcept Therapeutics surges as investors focus on a sizable insider buy and relacorilant’s next regulatory catalyst - Quiver Quantitative
Corcept Therapeutics (CORT) Jumps 43% Following FDA Approval of Key Drug - GuruFocus
US FDA approves Corcept Therapeutics' drug for hard-to-treat ovarian cancer - marketscreener.com
Corcept Therapeutics (CORT) Surges 10% Following FDA Approval of Cancer Treatment - GuruFocus
FDA Approves Corcept Therapeutics' (CORT) New Cancer Treatment - GuruFocus
Corcept Therapeutics stock surges on FDA cancer drug approval By Investing.com - Investing.com Canada
FDA Approves Relacorilant Combo in Platinum-Resistant Ovarian Cancers - CancerNetwork
Deadline Approaching for Investors of Corcept Therapeutics, Inc. (CORT)Contact Kaplan Fox Before April 21, 2026 - The National Law Review
Corcept Therapeutics (NASDAQ:CORT) Insider Sells $423,729.67 in Stock - MarketBeat
Assessing Corcept Therapeutics (CORT) Valuation After Recent Share Price Weakness And User Fair Value Debate - Yahoo Finance
Corcept Therapeutics Incorporated Securities Fraud Class Action Result of FDA Approval Issues and 50% Stock Decline - GlobeNewswire Inc.
Kaplan Fox Continues to Alert Investors of a Securities Class Act - The National Law Review
Corcept therapeutics exec Guyer sells $423,729 in shares By Investing.com - Investing.com Australia
CORT DEADLINE NOTICE: Corcept Therapeutics Incorporated - GlobeNewswire
Corcept therapeutics exec Guyer sells $423,729 in shares - Investing.com
[Form 4] CORCEPT THERAPEUTICS INC Insider Trading Activity - Stock Titan
Corcept (CORT) CDO exercises options and sells 11,767 shares - Stock Titan
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Corcept Therapeutics Incorporated of Class Action Lawsuit and Upcoming Deadlines – CORT - ChartMill
Shareholders who lost money in shares of Corcept Therapeutics (NASDAQ: CORT) should contact Wolf Haldenstein immediately - Finviz
CORT ALERT: Hagens Berman Alerts Corcept Therapeutics (CORT) Investors to Securities Class Action Following FDA Rejection and Federal Court Patent Loss - ChartMill
Bronstein, Gewirtz & Grossman LLC Urges Corcept - GlobeNewswire
CORT Shareholder Alert: April 21, 2026 Lead Plaintiff Deadline i - GuruFocus
CORT Shareholder Alert: April 21, 2026 Lead Plaintiff Deadline in Corcept Therapeutics Incorporated Securities Class Action Lawsuit -- The Gross Law Firm - PR Newswire
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Concorde International Group Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Corcept Therapeutics Incorporated (CORT) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
Levi & Korsinsky Reminds Corcept Therapeutics Incorporated - GlobeNewswire
Shareholders who lost money in shares of Corcept - GlobeNewswire
CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud ... - Caledonian Record
CORT ALERT: Hagens Berman Alerts Corcept Therapeutics - GlobeNewswire
Portnoy Law Firm Announces Class Action on Behalf of Corcept Therapeutics Incorporated Investors - GlobeNewswire
CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
CORT INVESTOR ALERT: Hagens Berman Alerts Corcept Therapeutics (CORT) Investors to Securities Class Action Following FDA Rejection and Federal Court Patent Loss - ChartMill
Corcept rises after insider buy worth over $3M - MSN
Corcept Therapeutics (NASDAQ:CORT) Shares Gap Up on Insider Buying Activity - MarketBeat
Zacks Research Issues Negative Estimate for CORT Earnings - MarketBeat
CORT’s FDA PDUFA Date on July 11: Approval Decision Creates a High-Stakes, High-Potential Trading Opportunity - Bitget
1.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):